All In Biotech

Drug Trial Radar · NCT00358215

RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin Alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects With Symptomatic Left Ventricular Systolic Dysfunction and Anemia

Last checked: Nov 20, 2026Latest source record: Nov 8, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,278 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,278

Actual

Start

Jun 1, 2006

Primary completion

Oct 11, 2012

Study completion Oct 11, 2012

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Jul 31, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to determine the efficacy of treatment of anemia with darbepoetin alfa compared to placebo on the composite of time to death from any cause or first hospital admission for worsening heart failure in patients with symptomatic left ventricular systolic dysfunction and anemia.

Conditions

  • Heart Failure
  • Anemia
  • Cardiovascular Disease
  • Ventricular Dysfunction
  • Congestive Heart Failure

Interventions

  • Darbepoetin alfaDrug

    Administered by subcutaneous injection

  • PlaceboDrug

    Placebo subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to All Cause Death or First Hospitalization for Worsening Heart FailureTime frame: From randomization to the end of study; maximum time on study was 73 months

Locations

754 sites in 36 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Birmingham, Alabama

  • Research Site

    Huntsville, Alabama

  • Research Site

    Mobile, Alabama

  • Research Site

    Gilbert, Arizona

  • Research Site

    Mesa, Arizona

  • Research Site

    Scottsdale, Arizona

  • Research Site

    Tucson, Arizona

  • Research Site

    Little Rock, Arkansas

  • Research Site

    Little Rock, Arkansas

  • Research Site

    Anaheim, California

  • Research Site

    Buena Park, California

  • Research Site

    Corona, California

  • Research Site

    Culver City, California

  • Research Site

    Downey, California

  • Research Site

    La Jolla, California

  • Research Site

    Lancaster, California

  • Research Site

    Larkspur, California

  • Research Site

    Loma Linda, California

  • Research Site

    Long Beach, California

  • Research Site

    Los Angeles, California

  • Research Site

    Los Angeles, California

  • Research Site

    Los Angeles, California

  • Research Site

    Los Angeles, California

  • Research Site

    Los Angeles, California

  • Research Site

    Modesto, California

  • Research Site

    Oakland, California

  • Research Site

    Pasadena, California

  • Research Site

    Redondo Beach, California

  • Research Site

    Sacramento, California

  • Research Site

    Sacramento, California

  • Research Site

    San Diego, California

  • Research Site

    San Francisco, California

  • Research Site

    San Francisco, California

  • Research Site

    Santa Monica, California

  • Research Site

    Santa Rosa, California

  • Research Site

    Sylmar, California

  • Research Site

    Walnut Creek, California

  • Research Site

    Westlake Village, California

  • Research Site

    Aurora, Colorado

Showing 40 of 754 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.